Leap Therapeutics, Inc. (LPTX)
LPTX moved a median of -0.37% 30 minutes after news, and +0.56% by the close. How LPTX actually reacts to news — the realized, point-in-time move the market made, measured across 158 labeled events over the last three years with zero look-ahead.
LPTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 52% | 144 |
| 30-min | -0.37% | 43% | 145 |
| 60-min | -1.16% | 42% | 145 |
| to close | +0.56% | 51% | 134 |
| Middle 50% of LPTX reactions | -3.42% to +2.80% |
|---|---|
| Median reaction (30-min) | -0.37% |
| Measured reactions | 158 |
Half of all Leap Therapeutics, Inc. news events land between -3.42% and +2.80% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LPTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LPTX's baseline. Nothing else.
Recent LPTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CYPHERPUNK TECHNOLOGIES For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEFA14A CYPHERPUNK TECHNOLOGIES | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 8-K CYPHERPUNK TECHNOLOGIES For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results | Press release | PR Newswire | +9.57% | — | |
| Form 10-Q LEAP THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +9.57% | — | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Nov 11 | SEC filing · Form 8-K | SEC EDGAR | +9.57% | — | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEFA14A LEAP THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy | Press release | PR Newswire | +9.57% | — | |
| Form DEF 14A LEAP THERAPEUTICS, INC. For: Dec 15 | SEC filing · Form DEF | SEC EDGAR | +1.37% | -5.63% | |
| Form DEFA14A LEAP THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +1.37% | -5.63% | |
| Form PRE 14A LEAP THERAPEUTICS, INC. For: Dec 15 | SEC filing · Form PRE | SEC EDGAR | +2.40% | +2.26% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -4.16% | -9.10% | |
| Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 | Press release | PR Newswire | -4.16% | -9.10% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -10.33% | |
| Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy | Press release | PR Newswire | +0.04% | -10.33% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -7.62% | -3.35% | |
| Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy | Press release | PR Newswire | -7.62% | -3.35% | |
| Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 | Press release | PR Newswire | +0.92% | +9.18% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +4.19% | +7.80% | |
| Form 10-Q LEAP THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.08% | -18.80% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -3.08% | -18.80% | |
| Leap Therapeutics Reports Second Quarter 2025 Financial Results | Press release | PR Newswire | -3.08% | -18.80% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -3.29% | -24.63% | |
| Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives | Press release | PR Newswire | -3.29% | -24.63% | |
| Form 10-Q LEAP THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.50% | +7.01% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +1.50% | +7.01% | |
| Leap Therapeutics Reports First Quarter 2025 Financial Results | Press release | PR Newswire | +1.50% | +7.01% | |
| Form ARS LEAP THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.44% | |
| Form DEF 14A LEAP THERAPEUTICS, INC. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +1.44% | |
| Form DEFA14A LEAP THERAPEUTICS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +1.44% | |
| Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting | Press release | PR Newswire | — | +2.54% | |
| Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | Press release | PR Newswire | -5.58% | +3.97% | |
| Form 10-K LEAP THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.79% | -3.51% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +2.79% | -3.51% | |
| Form S-8 LEAP THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | +3.12% | -11.02% | |
| Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Press release | PR Newswire | +2.79% | -3.51% | |
| Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study | Press release | PR Newswire | +2.79% | -3.51% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.68% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | -3.88% | -18.75% | |
| Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study | Press release | PR Newswire | -3.88% | -18.75% | |
| Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +1.19% | +0.00% | |
| Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference | Press release | PR Newswire | -0.40% | +5.16% | |
| Form 10-Q LEAP THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.77% | -7.69% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +6.77% | -7.69% | |
| Leap Therapeutics Reports Third Quarter 2024 Financial Results | Press release | PR Newswire | +6.77% | -7.69% | |
| Form S-8 LEAP THERAPEUTICS, INC. | SEC filing · Form S-8 | SEC EDGAR | -0.27% | -6.72% | |
| Form 8-K LEAP THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.86% | |
| Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients | Press release | PR Newswire | +0.00% | -5.86% | |
| Form 10-Q LEAP THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.53% | -4.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LPTX section they belong to.
Where else LPTX is measured.
LPTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Aptose Biosciences, Inc. - Common Shares (APTO) | 159 | -1.04% | 36% |
| NanoViricides, Inc. (NNVC) | 159 | +0.01% | 52% |
| MEI Pharma, Inc. (MEIP) | 158 | +0.11% | 52% |
| NeuroMetrix, Inc. (NURO) | 158 | -0.49% | 29% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Leap Therapeutics, Inc.'s median reaction calculated?
Every labeled LPTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 158 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of LPTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does LPTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.